1. Chen Y, Li H, Tang W, Zhu C, Jiang Y, Zou J, Yu Q, You Q (2009) 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. doi: 10.1016/j.ejmech.2008.12.008
2. Dallavalle S, Cincinelli R, Nannei R, Merlini L, Morini G, Penco S, Pisano C, Vesci L, Barbarino M, Zuco V, Cesare MD, Zunino F (2009) Design, synthesis and evaluation of bi-phenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase inhibitors. Eur J Med Chem. doi: 10.1016/j.ejmech.2008
3. Daniel D, Rejean R, Rico L, Carl R, Khalil AE (2001) Inhibitors of histone deacetylase. Methylgene Inc. International Patent Application, WO 01/38322 2001
4. Erden DD, Bora G, Ayhan P, Kocaefe C, Dalkara S, Yelekci K, Demir AS, Yurter HE (2009) Histone deacetylase inhibition activity and molecular docking of (E)-Resveratrol: its therapeutic potential in spinal muscular atrophy. Chem Biol Drug Des 73:355–364
5. Fang JY (2005) Histone deacetylase inhibitors, anti-cancerous mechanism and therapy for gastrointestinal cancers. J Gastroenterol Hepatol 20:988–994